Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biotech-bay entities : Amgen inc. save search
AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO
Published: 2023-11-01 (Crawled : 20:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.12%
H: 1.26%
C: -1.57%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.22%
H: 1.92%
C: 1.78%
pipeline
AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS
Published: 2023-10-25 (Crawled : 23:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.37%
H: 0.58%
C: -1.07%
financial results
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
Published: 2023-05-08 (Crawled : 23:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
RVMD S | $34.95 -2.46% -2.52% 1.2M
|
Health Technology
|
| O: 0.12%
H: 0.37%
C: 0.29%
BCEL P | $0.0761 0.0% 350K
|
Health Technology
|
| O: 3.0%
H: 1.94%
C: 1.94%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.5%
H: 0.17%
C: -0.31%
update financial results
NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE
Published: 2023-05-08 (Crawled : 15:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.73%
H: 0.92%
C: -0.08%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.5%
H: 0.17%
C: -0.31%
prolia risk
AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS
Published: 2023-02-22 (Crawled : 19:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.14%
H: 0.94%
C: -0.7%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.86%
H: 0.29%
C: -1.72%
risk association cardiovascular study
Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.
Published: 2023-01-11 (Crawled : 14:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.23%
H: 0.09%
C: -0.39%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.2%
H: 0.66%
C: 0.6%
WBA P | $18.25 3.75% 3.62% 11M
|
Retail Trade
|
| O: 1.36%
H: 0.24%
C: -0.22%
GERN | $3.69 -1.07% -1.08% 8.2M
|
Health Technology
|
| O: -0.91%
H: 3.36%
C: 0.92%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.76%
H: 0.32%
C: -1.11%
commercial
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136Advancement of Novel Cardiac Troponin Activator Expands Cardiovascular Franchise for Conditions Associated with Impaired Cardiac Contractility
Published: 2022-12-07 (Crawled : 13:00) - biospace.com/
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: -0.38%
H: 2.03%
C: 0.49%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.04%
H: 0.89%
C: 0.83%
ck-3828 cardiac cardiovascular study
AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022
Published: 2022-12-01 (Crawled : 19:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.59%
H: 3.87%
C: 2.15%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.56%
H: 0.03%
C: -0.72%
phase 1
Immune-Onc Therapeutics Appoints Two New Members to its Board of Directors
Published: 2022-11-08 (Crawled : 15:20) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 2.0%
H: 4.99%
C: 3.48%
therapeutics
AMGEN TO PRESENT NEW RESEARCH ACROSS SERIOUS INFLAMMATORY AND BONE DISEASES AT ACR 2022
Published: 2022-11-07 (Crawled : 18:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.07%
H: 6.5%
C: 2.87%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.33%
H: 3.48%
C: 3.31%
research bone
AMGEN ANNOUNCES WEBCAST OF 2022 CREDIT SUISSE GLOBAL HEALTHCARE CONFERENCE
Published: 2022-11-04 (Crawled : 21:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -1.48%
H: 2.81%
C: 2.71%
global conference
AMGEN'S ANNUAL TRENDS REPORT FINDS COMPETITION CREATED BY BIOSIMILARS CONTRIBUTED $21 BILLION IN U.S. HEALTHCARE SYSTEM SAVINGS
Published: 2022-10-12 (Crawled : 15:00) - biospace.com/
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: -0.08%
H: 0.13%
C: 0.13%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.77%
H: 20.74%
C: 17.3%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.44%
H: 1.79%
C: 0.85%
system trends report
AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Published: 2022-09-12 (Crawled : 22:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
america global conference
AMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
Published: 2022-09-08 (Crawled : 01:00) - biospace.com/
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -0.38%
H: 2.27%
C: 2.21%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.0%
H: 0.49%
C: 0.27%
global conference
IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors
Published: 2022-07-27 (Crawled : 11:00) - biospace.com/
IDYA | $37.1 -1.38% -1.4% 730K
|
Health Technology
|
| O: 1.12%
H: 2.86%
C: 1.89%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.79%
H: 1.44%
C: 1.03%
collaboration trial
AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
Published: 2022-04-27 (Crawled : 23:00) - biospace.com/
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.77%
H: 0.56%
C: -0.97%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.64%
H: 6.35%
C: 1.76%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.33%
H: 1.2%
C: -0.1%
results
AMGEN ANNOUNCES WEBCAST OF 2022 FIRST QUARTER FINANCIAL RESULTS
Published: 2022-04-22 (Crawled : 21:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
results
TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA
Published: 2022-01-13 (Crawled : 15:30) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.26%
H: 0.08%
C: -5.65%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
treatment
Amgen Announces New Data Being Presented At ASH 2021
Published: 2021-12-06 (Crawled : 23:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -11.5%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 2.53%
H: 0.0%
C: 0.0%
Amgen Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021
Published: 2021-10-07 (Crawled : 23:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.77%
H: 4.53%
C: 4.35%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.69%
H: 1.88%
C: 0.28%
phase 1 cancer phase 1b phase 2b
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.